Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary

M Orre, M Lotfi-Miri, P Mamers, P A Rogers, M Orre, M Lotfi-Miri, P Mamers, P A Rogers

Abstract

Microvessel density of benign, borderline and malignant ovarian tumours was studied immunohistochemically using antibodies to the endothelial cell markers CD31, CD34 and factor VIII-related antigen. Microvessel density was compared in tumours of different histological subtype, stage and patient outcome. CD31-immunostained sections were examined and regions of high and average microvessel density were selected. Identical regions were located on CD34- and factor VIII-related antigen-immunostained serial sections and microvessel counts obtained and converted to vessels mm(-2). CD31 and CD34 immunostaining revealed increased microvessel density in both the high and average vessel density regions of mucinous (222.4 +/- 24.8; 79.9 +/- 8.5) compared with serous (105.4 +/- 20.7; 33.3 +/- 6.8) and benign (84.4 +/- 19.4; 20.4 +/- 4.4) tumours (P < 0.001). CD31 and CD34 immunostaining also revealed increased microvessel density in early-stage mucinous tumours (234.6 +/- 28.2; 87.8 +/- 9.2) compared with that observed in both early- (72.8 +/- 15; 12.9 +/- 2.4) and late- (115.6 +/- 26.5; 29.8 +/- 8.5) stage serous tumours (P < 0.001). No differences in microvessel density in samples from patients with differing outcomes were observed (P > 0.05). Reduced factor VIII-related antigen compared with CD31 and CD34 immunostaining was observed in both borderline and malignant mucinous and serous tumours (P < 0.02) but not in benign tumours (P > 0.05). Our results contradict the putative association between increased microvessel density and poor prognosis and suggest that the level and control of angiogenesis may differ between ovarian tumour types.

References

    1. Cancer Res. 1974 May;34(5):997-1004
    1. Lancet. 1997 Jan 11;349(9045):113-7
    1. Cell. 1991 Jan 25;64(2):327-36
    1. Am J Pathol. 1991 Jun;138(6):1335-47
    1. Cancer Lett. 1992 Feb 29;62(2):153-8
    1. J Clin Pathol. 1992 Feb;45(2):143-8
    1. Int J Cancer. 1993 Sep 30;55(3):371-4
    1. Thromb Haemost. 1993 Jul 1;70(1):63-7
    1. J Natl Cancer Inst. 1994 Aug 17;86(16):1234-8
    1. Science. 1994 Sep 9;265(5178):1582-4
    1. Immunol Today. 1994 Oct;15(10):490-5
    1. J Cell Biochem Suppl. 1994;19:146-52
    1. Acta Neuropathol. 1994;88(5):454-8
    1. Jpn J Cancer Res. 1994 Dec;85(12):1247-56
    1. Anticancer Drugs. 1995 Feb;6(1):3-18
    1. Am J Pathol. 1995 Jul;147(1):33-41
    1. Am J Pathol. 1995 Jul;147(1):9-19
    1. Pathol Res Pract. 1995 Feb;191(1):25-30
    1. Cancer Res. 1995 Oct 15;55(20):4575-80
    1. Lancet. 1995 Nov 18;346(8986):1334-5
    1. Blood. 1996 Jan 1;87(1):1-13
    1. Int J Cancer. 1996 Jun 21;69(3):205-11
    1. Adv Cancer Res. 1985;43:175-203

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere